Endogenous and Therapeutic 25-Hydroxycholesterols May Worsen Early SARS-CoV-2 Pathogenesis in Mice

• Published in: American journal of respiratory cell and molecular biology Vol. 69; no. 6; pp. 638 - 648
• Main Authors: Fessler, Michael B, Madenspacher, Jennifer H, Baker, Paul J, Hilligan, Kerry L, Bohrer, Andrea C, Castro, Ehydel, Meacham, Julie, Chen, Shih-Heng, Johnson, Reed F, McDonald, Jeffrey G, Martin, Negin P, Tucker, Charles J, Mahapatra, Debabrata, Cesta, Mark, Mayer-Barber, Katrin D
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.12.2023
• Subjects: ACE2; Angiotensin; Angiotensin-converting enzyme 2; Animal models; Animals; Antiviral Agents - pharmacology; Antiviral drugs; Cholesterol; Coronaviruses; COVID-19; Cytokines; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Hydroxycholesterols - pharmacology; Mice; Pathogenesis; Peptidyl-dipeptidase A; Pneumonia; Receptors, G-Protein-Coupled; Rodents; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Side effects; Weight Loss; cholesterol-25-hydroxylase; 25-hydroxycholesterol; SARS-CoV-2; pneumonia; EBI2

Oxysterols (i.e., oxidized cholesterol species) have complex roles in biology. 25-Hydroxycholesterol (25HC), a product of the activity of cholesterol-25-hydroxylase (CH25H) on cholesterol, has recently been shown to be broadly antiviral, suggesting therapeutic potential against severe acute respirat...